• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS Pathog . Developing an appropriate evolutionary baseline model for the study of SARS-CoV-2 patient samples

tetano

Editor, Senior Moderator
PLoS Pathog


. 2023 Apr 5;19(4):e1011265.
doi: 10.1371/journal.ppat.1011265. eCollection 2023 Apr.
Developing an appropriate evolutionary baseline model for the study of SARS-CoV-2 patient samples


John W Terbot 2nd[SUP] 1 2 [/SUP], Parul Johri[SUP] 2 [/SUP], Schuyler W Liphardt[SUP] 1 [/SUP], Vivak Soni[SUP] 2 [/SUP], Susanne P Pfeifer[SUP] 2 [/SUP], Brandon S Cooper[SUP] 1 [/SUP], Jeffrey M Good[SUP] 1 [/SUP], Jeffrey D Jensen[SUP] 2 [/SUP]



Affiliations

Abstract

Over the past 3 years, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread through human populations in several waves, resulting in a global health crisis. In response, genomic surveillance efforts have proliferated in the hopes of tracking and anticipating the evolution of this virus, resulting in millions of patient isolates now being available in public databases. Yet, while there is a tremendous focus on identifying newly emerging adaptive viral variants, this quantification is far from trivial. Specifically, multiple co-occurring and interacting evolutionary processes are constantly in operation and must be jointly considered and modeled in order to perform accurate inference. We here outline critical individual components of such an evolutionary baseline model-mutation rates, recombination rates, the distribution of fitness effects, infection dynamics, and compartmentalization-and describe the current state of knowledge pertaining to the related parameters of each in SARS-CoV-2. We close with a series of recommendations for future clinical sampling, model construction, and statistical analysis.
 
Back
Top Bottom